JP2003524592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003524592A5 JP2003524592A5 JP2000557816A JP2000557816A JP2003524592A5 JP 2003524592 A5 JP2003524592 A5 JP 2003524592A5 JP 2000557816 A JP2000557816 A JP 2000557816A JP 2000557816 A JP2000557816 A JP 2000557816A JP 2003524592 A5 JP2003524592 A5 JP 2003524592A5
- Authority
- JP
- Japan
- Prior art keywords
- coating
- protective
- protective coating
- soluble
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011253 protective coating Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000004051 Gastric Juice Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Description
低pHで溶解する保護コーティングは、胃液(pH約1.5−3.0)中で容易に溶け、当該治療剤の下層コーティングに対して保護効果を有する物質なら、どんな物質であっても良い。少なくとも、当該保護コーティングは、当該治療剤のコーティングに対する磨耗を防止する効果を有し、水の吸収を減らし、個々の投与形態間の付着を抑えるようなものである。当該保護コーティングに使用できる物質の代表例として、Methocel(登録商標)および水溶性である他のセルロース化合物および糖類が存在する。前にも述べたように、低pHで可溶な保護コーティングは本発明における投与形態から除外することができる。しかし当該投与形態には、当該保護コーティングもこれを含めることが好ましい。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/111,188 US5968554A (en) | 1998-07-07 | 1998-07-07 | Sustained release pharmaceutical preparation |
US09/111,188 | 1998-07-07 | ||
US09/338,716 | 1999-06-23 | ||
US09/338,716 US6312728B1 (en) | 1998-07-07 | 1999-06-23 | Sustained release pharmaceutical preparation |
PCT/US1999/014204 WO2000001369A1 (en) | 1998-07-07 | 1999-06-25 | Sustained release pharmaceutical preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003524592A JP2003524592A (ja) | 2003-08-19 |
JP2003524592A5 true JP2003524592A5 (ja) | 2006-01-05 |
Family
ID=26808709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000557816A Pending JP2003524592A (ja) | 1998-07-07 | 1999-06-25 | 持続放出薬物製剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US6312728B1 (ja) |
EP (1) | EP1094790B9 (ja) |
JP (1) | JP2003524592A (ja) |
AT (1) | ATE274344T1 (ja) |
AU (1) | AU5084299A (ja) |
CA (1) | CA2337046C (ja) |
DE (1) | DE69919713T2 (ja) |
ES (1) | ES2226412T3 (ja) |
IL (1) | IL140761A0 (ja) |
WO (1) | WO2000001369A1 (ja) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9803871D0 (sv) * | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
US20030068356A1 (en) * | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
US6572889B1 (en) | 2002-03-07 | 2003-06-03 | Noveon Ip Holdings Corp. | Controlled release solid dosage carbamazepine formulations |
US20040043067A1 (en) * | 2002-06-19 | 2004-03-04 | Salamone Joseph C. | Fluorosiloxane matrix controlled diffusion drug delivery systems |
MY142204A (en) | 2002-07-25 | 2010-10-29 | Pharmacia Corp | Pramipexole once-daily dosage form |
JP2006507298A (ja) * | 2002-10-30 | 2006-03-02 | ファルマシア コーポレーション | 経口持続放出型錠剤、ならびにその製造法および使用法 |
US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
US20040253293A1 (en) * | 2003-06-16 | 2004-12-16 | Afshin Shafiee | Rate controlled release of a pharmaceutical agent in a biodegradable device |
WO2005030179A1 (en) * | 2003-09-29 | 2005-04-07 | Cj Corporation | Sustained-release formulations |
US7670624B2 (en) * | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
US7712288B2 (en) | 2004-05-28 | 2010-05-11 | Narayanan Ramasubramanian | Unified ingestion package and process for patient compliance with prescribed medication regimen |
US9592197B2 (en) * | 2004-12-16 | 2017-03-14 | Sovereign Pharmaceuticals, Llc | Dosage form containing diphenhydramine and another drug |
US20070003622A1 (en) * | 2004-12-16 | 2007-01-04 | Sovereign Pharmaceuticals, Ltd. | Diphenhydramine containing dosage form |
US20060034910A1 (en) * | 2004-08-09 | 2006-02-16 | Sanjay Patel | Pharmaceutical composition for extended release of phenytoin sodium |
CN101843597A (zh) | 2004-08-13 | 2010-09-29 | 贝林格尔·英格海姆国际有限公司 | 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途 |
SI1781260T2 (sl) | 2004-08-13 | 2014-08-29 | Boehringer Ingelheim International Gmbh | Tabletna formulacija s podaljšanim sproščanjem, ki vsebuje pramipeksol ali njegovo farmacevtsko sprejemljivo sol, postopek za izdelavo le-te in njena uporaba |
US20060134175A1 (en) * | 2004-12-22 | 2006-06-22 | Stephen Bartels | Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use |
US7529255B2 (en) * | 2005-04-21 | 2009-05-05 | Microsoft Corporation | Peer-to-peer multicasting using multiple transport protocols |
WO2007095523A2 (en) | 2006-02-13 | 2007-08-23 | Vanda Pharmaceuticals, Inc. | Stable dosage formulations of imidazolylalkyl-pyridines |
JP5228359B2 (ja) * | 2007-04-12 | 2013-07-03 | ニプロ株式会社 | 主薬粒子及びその製造方法ならびに口腔内崩壊錠 |
EP2152250B1 (en) * | 2007-05-07 | 2019-09-04 | Evonik Röhm GmbH | Solid dosage forms comprising an enteric coating with accelerated drug release |
AU2008334932B2 (en) | 2007-12-13 | 2014-05-22 | Vanda Pharmaceuticals Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
US8618134B2 (en) | 2007-12-13 | 2013-12-31 | Vanda Pharmaceuticals Inc. | Method and composition for treating a serotonin receptor-mediated condition |
US20090214665A1 (en) * | 2008-02-26 | 2009-08-27 | Lai Felix S | Controlled Release Muscarinic Receptor Antagonist Formulation |
US8663671B2 (en) * | 2009-11-05 | 2014-03-04 | Philip Morris Usa Inc. | Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity |
US8999393B1 (en) | 2013-01-09 | 2015-04-07 | Edgemont Pharmaceuticals Llc | Sustained release formulations of lorazepam |
KR20220128362A (ko) | 2019-12-27 | 2022-09-20 | 에벨로 바이오사이언시즈, 인크. | 박테리아 및 미생물 세포외 소포체를 함유하는 고체 투여 형태 |
WO2021146523A1 (en) | 2020-01-17 | 2021-07-22 | Evelo Biosciences, Inc. | Solid dosage forms with improved disintegration profiles |
EP4135670A1 (en) | 2020-04-17 | 2023-02-22 | Evelo Biosciences, Inc. | Solid dosage forms with improved disintegration profiles |
AU2021342481A1 (en) | 2020-09-18 | 2023-05-04 | Evelo Biosciences, Inc. | Solid dosage forms of bacteria |
KR20230127985A (ko) | 2020-10-29 | 2023-09-01 | 에벨로 바이오사이언시즈, 인크. | 스피룰리나 성분을 포함하는 조성물 |
EP4259806A1 (en) | 2020-12-14 | 2023-10-18 | Evelo Biosciences, Inc. | Extracellular vesicle preparations |
EP4267154A1 (en) | 2020-12-22 | 2023-11-01 | Evelo Biosciences, Inc. | Compositions comprising animal hemoglobin |
KR20230137968A (ko) | 2021-01-26 | 2023-10-05 | 에벨로 바이오사이언시즈, 인크. | 프레보텔라 세포외 소포체 제제 |
EP4297762A1 (en) | 2021-02-26 | 2024-01-03 | Evelo Biosciences, Inc. | Compositions and methods for reducing cytokine expression |
TW202302125A (zh) | 2021-03-05 | 2023-01-16 | 美商艾弗洛生物科技股份有限公司 | 固體劑型 |
TW202304415A (zh) | 2021-04-08 | 2023-02-01 | 美商艾弗洛生物科技股份有限公司 | 含有細菌的藥物製劑 |
WO2022221183A1 (en) | 2021-04-12 | 2022-10-20 | Evelo Biosciences, Inc. | Fournierella extracellular vesicle preparations |
WO2022251166A2 (en) | 2021-05-25 | 2022-12-01 | Evelo Biosciences, Inc. | Bacterial compositions comprising soy hemoglobin |
WO2023049268A1 (en) | 2021-09-24 | 2023-03-30 | Evelo Biosciences, Inc. | Solid dosage forms containing bacteria and microbial extracellular vesicles |
WO2023114293A1 (en) | 2021-12-14 | 2023-06-22 | Evelo Biosciences, Inc. | Extracellular vesicle assays |
WO2023114295A1 (en) | 2021-12-14 | 2023-06-22 | Evelo Biosciences, Inc. | Veillonella parvula bacteria extracellular vesicle preparations |
WO2023114300A1 (en) | 2021-12-14 | 2023-06-22 | Evelo Biosciences, Inc. | Fournierella massiliensis bacteria extracellular vesicle preparations |
WO2023146843A1 (en) | 2022-01-25 | 2023-08-03 | Evelo Biosciences, Inc. | Extracellular vesicle compositions and methods of use |
WO2023183396A1 (en) | 2022-03-22 | 2023-09-28 | Evelo Biosciences, Inc. | Compositions and methods of treating inflammation using prevotella histicola |
WO2023200837A1 (en) | 2022-04-13 | 2023-10-19 | Evelo Biosciences, Inc. | Compositions and methods of treating inflammation using prevotella histicola |
WO2023239728A1 (en) | 2022-06-07 | 2023-12-14 | Evelo Biosciences, Inc. | Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles |
WO2024102226A1 (en) | 2022-10-14 | 2024-05-16 | Evelo Biosciences, Inc. | Methods for assaying drug substances and drug products by using cell lines with nf-kb- inducible reporter genes |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994260A (en) | 1982-05-28 | 1991-02-19 | Astra Lakemedel Aktiebolag | Pharmaceutical mixture |
US5238686A (en) | 1986-03-27 | 1993-08-24 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
US4968508A (en) | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US5540945A (en) * | 1989-05-11 | 1996-07-30 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines |
ES2064564T3 (es) * | 1989-09-21 | 1995-02-01 | American Cyanamid Co | Sistema de liberacion pulsatil de dosis unitaria diaria de minociclina. |
ATE119766T1 (de) * | 1989-10-26 | 1995-04-15 | Nippon Shinyaku Co Ltd | Zubereitung für den magen. |
US5229131A (en) | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
US5188836A (en) | 1990-07-27 | 1993-02-23 | Warner-Lambert Company | Sustained release formulations |
US5102668A (en) | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
US5286493A (en) | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
DE19630035A1 (de) * | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
US5885616A (en) * | 1997-08-18 | 1999-03-23 | Impax Pharmaceuticals, Inc. | Sustained release drug delivery system suitable for oral administration |
US5968554A (en) * | 1998-07-07 | 1999-10-19 | Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. | Sustained release pharmaceutical preparation |
-
1999
- 1999-06-23 US US09/338,716 patent/US6312728B1/en not_active Expired - Lifetime
- 1999-06-25 AT AT99935347T patent/ATE274344T1/de not_active IP Right Cessation
- 1999-06-25 ES ES99935347T patent/ES2226412T3/es not_active Expired - Lifetime
- 1999-06-25 EP EP99935347A patent/EP1094790B9/en not_active Expired - Lifetime
- 1999-06-25 CA CA002337046A patent/CA2337046C/en not_active Expired - Lifetime
- 1999-06-25 WO PCT/US1999/014204 patent/WO2000001369A1/en active IP Right Grant
- 1999-06-25 AU AU50842/99A patent/AU5084299A/en not_active Abandoned
- 1999-06-25 DE DE69919713T patent/DE69919713T2/de not_active Expired - Lifetime
- 1999-06-25 IL IL14076199A patent/IL140761A0/xx unknown
- 1999-06-25 JP JP2000557816A patent/JP2003524592A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003524592A5 (ja) | ||
CA2213996A1 (en) | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate | |
HUP0103883A2 (hu) | Új, késleltetett felszabadulású, orális készítmények | |
CA2396159A1 (en) | Novel substituted benzimidazole dosage forms and method of using same | |
BR0212042A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto | |
CA2323680A1 (en) | Orally disintegrable tablets | |
JP2005516946A5 (ja) | ||
NO20015782D0 (no) | Kostblanding eller farmasöytisk sammensetning til anvendelse for forebyggelse eller behandling av hyperoksaluri | |
HUP0003691A2 (hu) | Gyorsan széteső, többrészes tabletták | |
MA26516A1 (fr) | Tartrate d'un dipeptide substitue, procede pour sa preparation et compositions pharmaceutiques le contenant. | |
CA2348451A1 (en) | Dosage forms containing taste masked active agents | |
DK1183014T3 (da) | Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse | |
CA2213987A1 (en) | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid | |
EP1698672A3 (de) | Beschichtungsmasse mit Biozidmikrokapseln | |
CA2457029A1 (en) | Breath freshening film | |
HUP0203168A2 (hu) | Készítmények nyálkahártyán át történő beadásra | |
ATE473006T1 (de) | Beschichtete teilchenförmige cefuroximeaxetil- zusammensetzungen | |
HUP0105313A3 (en) | Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use | |
CA2463030A1 (en) | Water-soluble pouches | |
CA2164776A1 (en) | Pharmaceutical, orally applicable composition | |
EP1181931A3 (en) | Intraoral adhesive preparation | |
JP2002127601A5 (ja) | ||
NO20021640D0 (no) | Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Ginko Biloba | |
DE60026481D1 (de) | Wässriges filmbildendes Überzugsmittel und oral anzuwendende feste Arzneizubereitung | |
RU93048335A (ru) | Оральная лекарственная форма, материал для оболочки |